• Portfolio
    • Next Investors
    • Catalyst Hunter
    • Wise-Owl
    • Next Biotech
    • Emerge
  • Latest Articles
  • Weekenders
  • Quick Takes
  • Education
  • Trust

  • Portfolio
    • Next Investors
    • Catalyst Hunter
    • Wise-Owl
    • Next Biotech
    • Emerge
  • Latest Articles
  • Weekenders
  • Quick Takes
  • Education
  • Trust
  1. Home
  2. Monepantel

Monepantel

Placeholder Image

PharmAust share price soars on release of results

Finfeed Archived Jun 18, 2020

PharmAust (ASX: PAA) received positive news regarding the performance of its treatments in reducing SARS-CoV-2 (COVID-19)

Placeholder Image

PharmAust shares soar following promising COVID-19 treatment results

Finfeed Archived Jun 04, 2020

PharmAust's (ASX:PAA) demonstrates both infectivity and replication of SARS-CoV-2 virus particles can be suppressed in cell cultures.

Placeholder Image

PharmAust's phase II monepantel trials a success

Finfeed Archived May 12, 2020

PharmAust (ASX: PAA) has released promising data in relation to its monepantel canine trial, investigating the anti-cancer effects of monepantel tablets in dogs.

Get expert stock analysis direct in your inbox

Join Our
Mailing List

Footer

Portfolio

  • Next Investors
  • Wise Owl
  • Catalyst Hunter
  • Next Biotech
  • Emerge

Support

  • Contact Us
  • Trust Centre
  • How it Works
  • History
  • FAQ
  • Definitions
  • Archived Articles
  • Bottom Drawer Portfolio

Policies

  • Customer Notice
  • Disclosure Policy
  • Financial Services Guide
  • ESG Policy
  • Privacy Policy

Subscribe Next Investors

Daily write ups on small cap stocks we are invested in:


Next Investors

This material has been prepared by S3 Consortium Pty Ltd (trading as StocksDigital). S3 Consortium Pty Ltd is a Corporate Authorised Representative (CAR 000433913) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, Price, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, Price, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.


© 2026 nextinvestors.com | All rights reserved

Follow Us